Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Petah Tikva, Israel.
Bipolar Disord. 2021 Feb;23(1):55-65. doi: 10.1111/bdi.12962. Epub 2020 Jul 25.
Recent evidence has associated mood disorders with blood-brain barrier (BBB)/ neurovascular unit (NVU) dysfunction, and reduction in blood vessels coverage by the water channel aquaporin-4 (AQP4) immunoreactive astrocytes. Lithium is an established treatment for mood disorders, yet, its mechanism of action is partially understood. We investigated the effects of lithium on BBB integrity and NVU-related protein expression in chronic mild stress (CMS) rat model of depressive-like behavior.
Male Wistar rats were exposed for 5 weeks to unpredictable mild stressors with daily co-administration of lithium chloride to half of the stressed and unstressed groups. Sucrose preference and open field tests were conducted to validate the depressive-like phenotype, and dynamic contrast-enhanced MRI analysis was utilized to assess BBB integrity in brain regions relevant to the pathophysiology of depression. Hippocampal AQP4 and claudin-5 expression were studied using immunofluorescence, western blot, and enzyme-linked immunosorbent assays.
Lithium administration to the stressed rats prevented the reductions in sucrose preference and distance traveled in the open field, and normalized the stress-induced hippocampal BBB hyperpermeability, whereas lithium administration to the unstressed rats increased hippocampal BBB permeability. Additionally, lithium treatment attenuated the decrease in hippocampal AQP4 to glial fibrillary acidic protein immunoreactivity ratio in the stressed rats and upregulated hippocampal claudin-5 and BDNF proteins expression.
Our findings suggest that lithium administration in a rat CMS model of depressive-like behavior is associated with attenuation of stressed-induced hippocampal BBB/NVU disruption. These protective effects may be relevant to the mode of action of lithium in depression.
最近的证据表明,情绪障碍与血脑屏障(BBB)/神经血管单元(NVU)功能障碍有关,水通道蛋白-4(AQP4)免疫反应性星形胶质细胞减少了血管的覆盖。锂是一种治疗情绪障碍的成熟药物,但它的作用机制尚不完全清楚。我们研究了锂对慢性轻度应激(CMS)大鼠抑郁样行为模型中 BBB 完整性和与 NVU 相关蛋白表达的影响。
雄性 Wistar 大鼠连续 5 周暴露于不可预测的轻度应激源中,同时对一半应激组和非应激组大鼠给予氯化锂共同给药。通过蔗糖偏好和旷场试验验证抑郁样表型,利用动态对比增强 MRI 分析评估与抑郁病理生理学相关的脑区 BBB 完整性。使用免疫荧光、Western blot 和酶联免疫吸附试验研究海马 AQP4 和 Claudin-5 的表达。
锂对应激大鼠的给药可防止蔗糖偏好和旷场中距离的减少,并使应激诱导的海马 BBB 高通透性正常化,而锂对非应激大鼠的给药增加了海马 BBB 的通透性。此外,锂处理可减轻应激大鼠海马 AQP4 与胶质纤维酸性蛋白免疫反应性比值的下降,并上调海马 Claudin-5 和 BDNF 蛋白的表达。
我们的研究结果表明,锂在抑郁样行为的 CMS 大鼠模型中的给药与减轻应激诱导的海马 BBB/NVU 破坏有关。这些保护作用可能与锂在抑郁症中的作用机制有关。